# K062205: DBX Strip

- Pathway: 510(k) (Traditional)
- Applicant: Musculoskeletal Transplant Foundation
- Decided: Feb 5, 2007 after 188 days
- Product code: MBP (Filler, Bone Void, Osteoinduction (W/O Human Growth Factor))
- Device class: 2
- Regulation: 21 CFR 888.3045
- Recalls of this device: none
- Data: FDA decisions to Oct 25, 2026; recalls to Oct 12, 2026

## Lineage
Longest line of descent: 1 generation back to K042829 (2006). 1 ancestor in all.
6 later devices descend from it; 4 cite it directly.
0 of 8 devices in its family (counting itself) have a Class I recall.

## Predicates on the family tree (from the FDA summary)
- K042829: DBX Strip, Musculoskeletal Transplant Foundation (2006) Summary page 2.

## Most influential descendants
- K113167: MTF New Bone Voild Filler (2012), 3 descendants of its own
- K110003: MTF New Bone Void Filler (2011), 3 descendants of its own
- K121989: Optecure Bone Void Filler (0.5 CC, 1CC, 2CC, 5CC, 10CC, and 20CC), Optecure + CCC Bone Void Filler (1CC, 2CC, 5CC, 10CC, (2012), 1 descendant of its own
- K241555: Moldable Bone Void Filler and Moldable Bone Void Filler + CCC (2025), 0 descendants of its own
- K151271: BellaFuse (2016), 0 descendants of its own

## Indications for use
DBX® Strip is indicated as a bone void filler for treatment of surgically created osseous voids or gaps that are not intrinsic to the stability of the bony structure. It can be used in the pelvis, extremities, and the posterolateral spine for posterolateral fusion. DBX® Strip, when used for posterolateral spine fusion, may be used with autograft. DBX ®Strip is for single patient use only.

Source page: https://510kreport.com/device/K062205
Methodology: https://510kreport.com/methodology